Shanghai Junshi Biosciences (1877.HK, 688180.SH) Announces Progress on Chairman’s Shareholding Increase Plan

Bulletin Express
11/10

Shanghai Junshi Biosciences Co., Ltd. has issued an update regarding a shareholding increase by its controlling shareholder, actual controller, and chairman of its Board of Directors, Xiong Jun. According to the announcement, Xiong Jun plans to acquire no less than RMB100 million worth of the company’s A shares and H shares over a 12-month period beginning 12 April 2025, with at least RMB50 million earmarked specifically for A shares.

As of the latest disclosure, Xiong Jun purchased 100,000 A shares on 10 November 2025 via centralized bidding on the Shanghai Stock Exchange. The total transaction amount reached RMB3,838,400, representing approximately 0.01% of the company’s total share capital. Together with other parties acting in concert, the controlling shareholders and actual controllers currently hold 184,083,186 shares, accounting for about 17.93% of the total share capital. The company emphasizes that the shareholding increase plan is continuing, with the potential for changes due to market conditions, though there is no impact on the firm’s overall ownership structure.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10